-
Baxalta Incorporated et al v. Genentech, Inc. et al DC CAFC
- 1:17-cv-00509
- D. Del.
- Judge: Timothy B. Dyk
- Filed: 05/04/2017
- Latest Docket Entry: 11/14/2023
- PACER
2
Plaintiffs
2
Defendants
1
Accused
Product
1
Patent-in-Suit
2,406
Days in
Litigation
-
Baxalta Incorporated et al v. Genentech, Inc. et al DC CAFC
- 1:17-cv-00509
- D. Del.
- Judge: Timothy B. Dyk
- Filed: 05/04/2017
- Latest Docket Entry: 11/14/2023
- PACER
Causes of Action
Infringement
Willful Patent Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
An isolated antibody or antibody fragment thereof that binds Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa.
|
Invalid
Entry 574 |
| 2 |
The antibody or antibody fragment according to claim 1 that increases the procoagulant activity of Factor IXa in the presence of Factor VIII inhibitors.
|
Invalid
Entry 574 |
| 3 |
The antibody or antibody fragment according to claim 1 wherein the antibody is an IgG, IgM, IgA or IgE antibody.
|
Invalid
Entry 574 |
| 4 |
The antibody or antibody fragment according to claim 1, wherein said antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a bispecific
view more
|
Invalid
Entry 574 |
| 19 |
The antibody or antibody fragment according to claim 4, wherein the antibody is a humanized antibody.
|
Invalid
Entry 574 |
| 20 |
The antibody or antibody fragment according to claim 2 wherein the antibody is selected from the group consisting of an IgG, IgM, IgA or IgE antibody.
|
Invalid
Entry 574 |
-
Infringement
Genentech, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Emicizumab | US 7,033,590 B1 |
1, 4, 15, 17, 19
|
No infringement
Entry 334
|
